Last reviewed · How we verify

Polyunsaturated fatty acids omega-3

Hospital San Juan de la Cruz · Phase 3 active Small molecule

Omega-3 polyunsaturated fatty acids reduce triglycerides and modulate inflammatory pathways by incorporating into cell membranes and competing with pro-inflammatory arachidonic acid metabolites.

Omega-3 polyunsaturated fatty acids reduce triglycerides and modulate inflammatory pathways by incorporating into cell membranes and competing with pro-inflammatory arachidonic acid metabolites. Used for Hypertriglyceridemia, Cardiovascular disease prevention, Post-myocardial infarction secondary prevention.

At a glance

Generic namePolyunsaturated fatty acids omega-3
SponsorHospital San Juan de la Cruz
Drug classLipid-modifying agent; nutraceutical
TargetMultiple: GPR120, GPR40, PPAR-γ, LXR; membrane incorporation
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Omega-3 PUFAs (EPA and DHA) are incorporated into phospholipid membranes where they displace arachidonic acid, reducing production of pro-inflammatory eicosanoids and cytokines. They also activate G-protein coupled receptors and nuclear receptors (PPAR-γ, LXR) that suppress inflammatory gene expression and improve lipid metabolism, particularly reducing plasma triglycerides.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results